{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:24:49Z","timestamp":1788312289686,"version":"build-2803163510"},"reference-count":95,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>\n            Although innovation in cancer treatment has improved cure rates and survival, the costs have escalated beyond societies' ability to pay. Cancer care costs in the United States are expected to rise to 245 billion by 2030. In this health policy session, we focused on three cost-containment strategies, and their potential impact on cancer care delivery.\n            <jats:italic toggle=\"yes\">Site Neutrality: Curbing the Cost of Cancer Care, but at What Risk?<\/jats:italic>\n            , explores legislation that would introduce payment parity across differing sites of care: elimination of facility fees in hospital owned practices and shift of billing for oncology infusions away from hospital owned practices. Unintended consequences could reduce access to care for vulnerable populations, shift costs to patients, and reduce safety.\n            <jats:italic toggle=\"yes\">Post-Pandemic Digital Health Reimbursement: Impact on Access to Care<\/jats:italic>\n            , explores how the emergency waivers, licensure flexibilities, and parity reimbursement necessitated by COVID-19 shepherded innovation that outpaced the regulatory framework needed for long-term sustainability. Today, telehealth services, hospital at home, remote patient monitoring, and decentralized clinical trial enrollment face reintroduction of regulatory and payment barriers.\n            <jats:italic toggle=\"yes\">Will we live to see efficacy-based pricing for cancer drugs? Learning from international models<\/jats:italic>\n            , explores how lack of drug price negotiation has led to higher prices in the United States compared with Canada and Europe. Comparative clinical effectiveness pricing systems compare the value of each drug to standard treatments. Comparative cost-effectiveness programs look at the incremental cost per additional unit of health gained above the standard of care. The United States could learn from these approaches used in comparable countries.\n          <\/jats:p>","DOI":"10.1200\/edbk-25-473822","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:59:06Z","timestamp":1750190346000},"source":"Crossref","is-referenced-by-count":2,"title":["Proposed Policy Changes to Cancer Care and Oncologic Drug Reimbursement: Exploring the Rationale and Anticipating the Consequences"],"prefix":"10.1200","volume":"45","author":[{"given":"Ryan W.","family":"Huey","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Pritchett","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN"},{"name":"Department of Community Oncology, Mayo Clinic Health System, La Crosse, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin N.","family":"Vokinger","sequence":"additional","affiliation":[{"name":"ETH Zurich and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Swenson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND"},{"name":"Lakewood Health System, Staples, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tufia C.","family":"Haddad","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerin","family":"Adelson","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-1534"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191912366"},{"key":"e_1_3_4_4_2","unstructured":"Nabi J Trinh Q-D: New cancer therapies are great\u2014But are they helping everyone? https:\/\/www.healthaffairs.org\/content\/forefront\/new-cancer-therapies-great-but-they-helping-everyone"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2012.1263"},{"key":"e_1_3_4_6_2","unstructured":"Business Group on Health: Cancer now top driver of employer health care costs says business group\u2019s 2023 health care strategy and plan design survey. https:\/\/www.businessgrouphealth.org\/en\/newsroom\/news-and-press-releases\/press-releases\/2023-lehcspds"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5544"},{"key":"e_1_3_4_8_2","unstructured":"Alliance CO: 2020 Community Oncology Alliance Practice Impact Report 2020. https:\/\/communityoncology.org\/wp-content\/uploads\/2020\/04\/COA_PracticeImpactReport2020_FINAL.pdf"},{"key":"e_1_3_4_9_2","unstructured":"Chartis Group: Hospital and oncology physician alignment. Chartis 2020. https:\/\/www.chartis.com\/insights\/hospital-and-oncology-physician-alignment"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4753"},{"key":"e_1_3_4_11_2","unstructured":"Fronstin P Roebuck MC Stuart BC: Location location location: Cost differences for oncology medicines based on site of treatment 2020. https:\/\/www.ebri.org\/docs\/default-source\/pbriefs\/ebri_ib_498_chemocosts-16jan20.pdf"},{"key":"e_1_3_4_12_2","unstructured":"Medicare Payment Advisory Commission: June 2019 report to the congress: Medicare and the health care delivery system 2019. https:\/\/www.medpac.gov\/wp-content\/uploads\/import_data\/scrape_files\/docs\/default-source\/reports\/jun19_medpac_reporttocongress_sec.pdf"},{"key":"e_1_3_4_13_2","unstructured":"American Hospital Association: Fact sheet: Medicare hospital outpatient site-neutral payment policies. AHA 2023. https:\/\/www.aha.org\/fact-sheets\/2023-03-21-fact-sheet-medicare-hospital-outpatient-site-neutral-payment-policies"},{"key":"e_1_3_4_14_2","unstructured":"Cooper Z Jurinka E Stern D: Site-neutral payment literature review 2023. https:\/\/tobin.yale.edu\/sites\/default\/files\/2023-10\/Site-Neutral%20Payment%20Literature%20Review%2010302023.pdf"},{"key":"e_1_3_4_15_2","unstructured":"American Hospital Association: Hospitals and health systems are critical to preserving access to care for rural communities 2024. https:\/\/www.aha.org\/system\/files\/media\/file\/2024\/01\/analysis-hospitals-health-systems-are-critical-to-preserving-access-to-care-for-rural-communities-report.pdf"},{"key":"e_1_3_4_16_2","unstructured":"National Rural Health Association: Overcoming barriers to sustainable growth in rural hospitals 2025. https:\/\/www.ruralhealth.us\/blogs\/2025\/02\/overcoming-barriers-to-sustainable-growth-in-rural-hospitals"},{"key":"e_1_3_4_17_2","unstructured":"Sheps Center for Health Services: Rural hospital closures. University of North Carolina at Chapel Hill. https:\/\/www.shepscenter.unc.edu\/programs-projects\/rural-health\/rural-hospital-closures\/"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2019.00916"},{"key":"e_1_3_4_19_2","unstructured":"Centers for Medicare and Medicaid Services: Revised hospital guidance for pharmaceutical services and expanded guidance related to compounding of medications. https:\/\/www.cms.gov\/medicare\/provider-enrollment-and-certification\/surveycertificationgeninfo\/downloads\/survey-and-cert-letter-16-01.pdf"},{"key":"e_1_3_4_20_2","unstructured":"Reference deleted"},{"key":"e_1_3_4_21_2","unstructured":"Mary C: Comprehensive cancer care adds value\u2014The challenge is paying for it ACCC survey finds. https:\/\/www.ajmc.com\/view\/comprehensive-cancer-care-adds-value-the-challenge-is-paying-for-it-accc-survey-finds"},{"key":"e_1_3_4_22_2","unstructured":"Crouch M Ledger C: When your doctor\u2019s visit comes with a hospital fee\u2014But no hospital. North Carolina Health News. https:\/\/www.northcarolinahealthnews.org\/2024\/09\/23\/hospital-facility-fees-but-no-hospital"},{"key":"e_1_3_4_23_2","unstructured":"IfCaE Review: ICER white paper: White bagging brown bagging and site of service policies 2023. https:\/\/icer.org\/wp-content\/uploads\/2023\/04\/ICER-White-Paper-_-White-Bagging-Brown-Bagging-and-Site-of-Service-Policies.pdf"},{"key":"e_1_3_4_24_2","unstructured":"American Cancer Society Cancer Action Network: Examining the impact of site neutral payment on costs for cancer care. American Cancer Society. https:\/\/www.fightcancer.org\/sites\/default\/files\/acs_can_site_neutral_issue_brief_-_final_10-19-23.pdf"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00438"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgae021"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390678"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01534-5"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00118"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.29958"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200141"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03507-y"},{"key":"e_1_3_4_33_2","article-title":"Remote patient monitoring to transform management of febrile neutropenia in cancer patients","volume":"5","author":"Pritchett JC","year":"2024","unstructured":"Pritchett JC, Paludo JC, Borah BJ, et al: Remote patient monitoring to transform management of febrile neutropenia in cancer patients. NEJM Catal Innov Care Deliv 5, 2024. https:\/\/catalyst.nejm.org\/doi\/full\/10.1056\/CAT.23.0365","journal-title":"NEJM Catal Innov Care Deliv"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01788-1"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-022-00663-0"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2023.05.003"},{"key":"e_1_3_4_38_2","article-title":"Accelerating the delivery of cancer care at home during the Covid-19 pandemic","volume":"1","author":"Laughlin AI","year":"2020","unstructured":"Laughlin AI, Begley M, Delaney T, et al: Accelerating the delivery of cancer care at home during the Covid-19 pandemic. NEJM Catal Innov CareDeliv 1, 2020. https:\/\/catalyst.nejm.org\/doi\/full\/10.1056\/CAT.20.0258","journal-title":"NEJM Catal Innov CareDeliv"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00961"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-074030"},{"key":"e_1_3_4_41_2","article-title":"Tenets for implementing electronic patient-reported outcomes for remote symptom monitoring during cancer treatment","author":"Basch E","unstructured":"Basch E, Rocque G, Mody G, et al: Tenets for implementing electronic patient-reported outcomes for remote symptom monitoring during cancer treatment. JCO Clin Cancer Inform 10.1200\/CCI.22.00187","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_4_42_2","unstructured":"The Commonwealth Fund: The impact of the COVID-19 pandemic on outpatient visits: A rebound emerges. https:\/\/www.commonwealthfund.org\/publications\/2020\/apr\/impact-covid-19-outpatient-visits"},{"key":"e_1_3_4_43_2","unstructured":"Code of Federal Regulations: Title 42\u2014\u00a7 410.78 telehealth services. https:\/\/www.ecfr.gov\/current\/title-42\/chapter-IV\/subchapter-B\/part-410\/subpart-B\/section-410.78"},{"key":"e_1_3_4_44_2","unstructured":"Centers for Medicare & Medicaid Services: Medicare and Medicaid programs; CY 2025 payment policies under the physician fee schedule and other changes to part B payment and coverage policies; Medicare shared savings program requirements; Medicare prescription drug inflation rebate program; and Medicare overpayments. https:\/\/public-inspection.federalregister.gov\/2024-25382.pdf"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.5928"},{"key":"e_1_3_4_46_2","unstructured":"Interstate Medical Licensure Compact: U.S. state participation in the compact. https:\/\/imlcc.com\/"},{"key":"e_1_3_4_47_2","unstructured":"Bestsennyy O Gilbert G Harris A et al: Telehealth: A quarter-trillion-dollar post-COVID-19 reality? https:\/\/www.mckinsey.com\/industries\/healthcare\/our-insights\/telehealth-a-quarter-trillion-dollar-post-covid-19-reality"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.45363"},{"key":"e_1_3_4_49_2","unstructured":"Centers for Medicare & Medicaid Services: Calendar year (CY) 2025 Medicare physician fee schedule final rule. https:\/\/www.cms.gov\/newsroom\/fact-sheets\/calendar-year-cy-2025-medicare-physician-fee-schedule-final-rule"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00565"},{"key":"e_1_3_4_51_2","article-title":"Electronic patient-reported outcomes in oncology: Lessons from six cancer centers","volume":"5","author":"Cronin C","year":"2024","unstructured":"Cronin C, Barrett F, Dias S, et al: Electronic patient-reported outcomes in oncology: Lessons from six cancer centers. NEJM Catal Innov Care Deliv 5, 2024. https:\/\/catalyst.nejm.org\/doi\/full\/10.1056\/CAT.23.0331","journal-title":"NEJM Catal Innov Care Deliv"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149103"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187186"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00676"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00307"},{"key":"e_1_3_4_56_2","unstructured":"Centers for Medicare & Medicaid Services: Fact sheet: Report on the study of the acute hospital care at home initiative. https:\/\/www.cms.gov\/newsroom\/fact-sheets\/fact-sheet-report-study-acute-hospital-care-home-initiative"},{"key":"e_1_3_4_57_2","article-title":"Acute hospital care at home: The CMS waiver experience","volume":"2","author":"Clarke DV","year":"2021","unstructured":"Clarke DV, Newsam J, Olson DP, et al: Acute hospital care at home: The CMS waiver experience. NEJM Catal Innov Care Deliv 2, 2021. https:\/\/catalyst.nejm.org\/doi\/full\/10.1056\/CAT.21.0338","journal-title":"NEJM Catal Innov Care Deliv"},{"key":"e_1_3_4_58_2","unstructured":"Centers for Medicare & Medicaid Services: Lessons from CMS\u2019 acute hospital care at home initiative. https:\/\/www.cms.gov\/blog\/lessons-cms-acute-hospital-care-home-initiative"},{"key":"e_1_3_4_59_2","unstructured":"Leff B Levine DM Siu AL: The acute hospital care at home waiver and the future of hospital at home in the US. https:\/\/www.healthaffairs.org\/content\/forefront\/acute-hospital-care-home-waiver-and-future-hospital-home-us"},{"key":"e_1_3_4_60_2","unstructured":"Centers for Medicare & Medicaid Services: Approved facilities\/systems for acute hospital care at home. https:\/\/qualitynet.cms.gov\/acute-hospital-care-at-home\/resources"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00088"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpdig.2023.06.015"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.6228"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0302-y"},{"key":"e_1_3_4_65_2","unstructured":"U.S. Food and Drug Administration: Guidance document: Conducting clinical trials with decentralized elements. FDA-2022-D-2870. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/conducting-clinical-trials-decentralized-elements"},{"key":"e_1_3_4_66_2","unstructured":"Centers for Medicare & Medicaid Services: [CMS-1809-P]: Medicare and Medicaid programs: Hospital outpatient prospective payment and ambulatory surgical center payment systems; quality reporting programs including the hospital inpatient quality reporting program; health and safety standards for obstetrical services in hospitals and critical access hospitals; prior authorization; requests for information; Medicaid and CHIP continuous eligibility; Medicaid clinic services four walls exceptions; individuals currently or formerly in custody of penal authorities; revision to Medicare special enrollment period for formerly incarcerated individuals; and all-inclusive rate add-on payment for high-cost drugs provided by indian health service and tribal facilities. https:\/\/public-inspection.federalregister.gov\/2024-25521.pdf"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.5694\/mja12.10480"},{"key":"e_1_3_4_68_2","unstructured":"U.S. 118th Congress (2023-2024). S.368\u2014Aviation WORKS Act. https:\/\/www.congress.gov\/bill\/118th-congress\/senate-bill\/368"},{"key":"e_1_3_4_69_2","unstructured":"Health Resources & Services Administration: Medicare telehealth payment eligibility analyzer. https:\/\/data.hrsa.gov\/tools\/medicare\/telehealth"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.019"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21730"},{"key":"e_1_3_4_72_2","unstructured":"National Cancer Institute: Financial toxicity (financial distress) and cancer treatment. https:\/\/www.cancer.gov\/about-cancer\/managing-care\/track-care-costs\/financial-toxicity-pdq"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7987"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5542"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102087"},{"key":"e_1_3_4_76_2","unstructured":"U.S. 117th Congress (2021-2022). H.R.5376\u2014Inflation Reduction Act of 2022. https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/5376"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15268"},{"key":"e_1_3_4_78_2","unstructured":"Centers for Medicare & Medicaid Services: Medicare drug price negotiation program: Negotiated prices for initial price applicability year 2026. https:\/\/www.cms.gov\/newsroom\/fact-sheets\/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2411265"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.4461"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.4801"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1177\/1073110520958885"},{"key":"e_1_3_4_83_2","unstructured":"Institute for Clinical and Economic Review: Cost-effectiveness the QALY and the evLYG. https:\/\/icer.org\/our-approach\/methods-process\/cost-effectiveness-the-qaly-and-the-evlyg\/"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.07.017"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2015.11.007"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2026"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.031"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.53438"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2022.01.013"},{"key":"e_1_3_4_90_2","unstructured":"National Institute for Health and Care Excellence: Should NICE\u2019s cost-effectiveness thresholds change? https:\/\/www.nice.org.uk\/news\/blogs\/should-nice-s-cost-effectiveness-thresholds-change"},{"key":"e_1_3_4_91_2","unstructured":"National Institute for Health and Care Excellence: NICE health technology evaluations: The manual. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation-2"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02352-3"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-024-00511-9"},{"key":"e_1_3_4_94_2","unstructured":"Canadian Agency for Drugs and Technologies in Health: Guidelines for the economic evaluation of health technologies: Canada 4th edition 2017. https:\/\/www.cda-amc.ca\/sites\/default\/files\/pdf\/economic_guidelines_worked_example.pdf"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2396"},{"key":"e_1_3_4_96_2","unstructured":"Swiss Federal Council: 65d KVV (Verordnung \u00dcber Die Krankenversicherung SR 832.102). https:\/\/www.fedlex.admin.ch\/eli\/cc\/1995\/3867_3867_3867\/de"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-473822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:59:13Z","timestamp":1750190353000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-473822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/EDBK-25-473822"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-473822","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"e473822"}}